AbbVie Inc. filings document formal disclosures for a global pharmaceutical issuer with common stock and multiple senior note series registered on the New York Stock Exchange. Recent Form 8-K reports cover quarterly and annual results, preliminary earnings impacts from acquired IPR&D and milestone expenses, material-event disclosures, material agreements and capital-structure updates.
The company’s filing record also includes debt-financing disclosures for completed senior note offerings and definitive proxy materials covering board matters, executive compensation, equity awards and shareholder voting items. These documents provide regulatory detail on AbbVie’s operating results, listed securities, governance framework and financing activity.
Robert J. Alpern, an AbbVie director, reported a Form 4 disclosing a non‑derivative acquisition on 09/30/2025 of 33 stock equivalent units credited at a per‑unit value of $231.54. The filing states these units are director fees credited to grantor trust accounts established by Abbott Laboratories and AbbVie and that AbbVie account units are payable in cash generally at age 65 or upon retirement from AbbVie’s board. The report shows a total beneficial ownership balance of 10,151 stock equivalent units (including amounts from dividend reinvestment). The Form 4 was signed by an attorney‑in‑fact on 10/02/2025.
AbbVie Inc. reported that it has settled litigation with all generic drug manufacturers that filed abbreviated new drug applications in the United States for generic versions of its upadacitinib tablets, marketed as RINVOQ. Based on these settlement and license agreements, and assuming pediatric exclusivity is granted, AbbVie does not expect any generic upadacitinib tablet products to enter the U.S. market before April 2037, subject to standard acceleration provisions in the agreements.
The company also reiterated that these expectations are forward-looking and could be affected by factors such as intellectual property challenges, litigation outcomes, regulatory changes, and broader business risks described in its prior annual and quarterly reports.
AbbVie Inc. (ABBV) Form 144 notice: An insider proposes to sell 62,755 shares of common stock through Morgan Stanley Smith Barney LLC on 08/22/2025. The shares were acquired the same day via a stock option exercise and paid for in cash. The filing lists an aggregate market value for the proposed sale of $13,231,264.20 and reports 1,766,558,253 shares outstanding for the class. The filer also reported four prior common-stock sales in August 2025 by Richard A. Gonzalez: 61,500 shares on 08/01/2025 (gross proceeds $12,043,268.25), 35,120 shares and 91,600 shares on 08/04/2025 (gross proceeds $6,828,296.22 and $19,208,000.00 respectively), and 90,000 shares on 08/21/2025 (gross proceeds $18,993,947.76). The filer certifies no undisclosed material adverse information and acknowledges legal penalties for false statements.
AbbVie insider sale notice: This Form 144 shows that Richard A. Gonzalez intends to sell 90,000 AbbVie (ABBV) common shares through Morgan Stanley Smith Barney on 08/21/2025 with an aggregate market value of $18,993,947.76. The filing reports Abbies outstanding shares as 1,766,558,253, so the planned sale represents a small fraction of total shares. The 90,000 shares were acquired the same day, 08/21/2025, by stock option exercise and paid for in cash.
The filing also discloses recent insider sales by Richard A. Gonzalez during the past three months: 61,500 shares sold 08/01/2025 for $12,043,268.25; 35,120 shares sold 08/04/2025 for $6,828,296.22; and 91,600 shares sold 08/04/2025 for $19,208,000. The notice includes the standard insider representation that no undisclosed material adverse information is known.
AbbVie EVP and Chief Operations Officer Azita Saleki‑Gerhardt exercised an employee stock option for 42,370 shares of common stock at $54.86 per share, then sold 42,370 shares on August 12, 2025 at a weighted‑average price of about $198.42, based on multiple trades between $198.34 and $198.58 per share. Following these transactions she holds 177,292 AbbVie shares directly, plus indirect interests including 2,647 shares in an AbbVie savings program and 3,873 shares held by her spouse, for which she disclaims beneficial ownership.
AbbVie filed a Form 144 reporting a proposed sale of 42,370 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $8,407,068.11. The filing lists the approximate date of sale as 08/12/2025 and shows the shares were acquired by a stock option exercise on 08/12/2025 with payment in cash.
The notice states there were no securities sold in the past three months by the person for whose account the shares are to be sold. The filing includes the total number of shares outstanding as 1,766,558,253, and identifies the executing broker and the class of security as common stock. No additional transaction context or identities are provided in the document.
AbbVie (ABBV) filed a Form 144 reporting proposed sales of common stock through Northern Trust Securities on the NYSE. The notice lists three proposed transactions: 61,500 shares (aggregate market value $12,043,268.25, approx. sale date 08/01/2025), 35,120 shares ($6,828,296.22, 08/04/2025) and 91,600 shares ($19,208,000, 08/04/2025). The filing shows a reported number of outstanding shares of 1,766,558,253.
The document discloses the acquisition history for the securities to be sold, showing they were received as restricted stock in grants dated between 02/28/2017 and 02/26/2021 with specific grant amounts listed. The filer indicates no securities sold in the past three months and includes the standard Rule 144 attestation about lack of undisclosed material adverse information.